

Product Data Sheet

Product Name: PROTAC JAK1/2 degrader-1

Cat. No.: GC80946

Chemical Properties

Cas. No.


Formula $C_{33}H_{29}N_7O_5$ M.Wt 603.63

Solubility DMSO: 100 mg/mL (165.66 mM); ultrasonic and warming and heat to 60°C) Storage Store at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution: ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure



Background

PROTAC JAK1/2 degrader-1 is an orally active JAK1 / JAK2 PROTAC degrader, with DC_{50} values of 1.4 μ M and 0.92 μ M against JAK1 and JAK2, respectively. PROTAC JAK1/2 degrader-1 triggers degradation via a CRBN- and proteasome-dependent pathway. PROTAC JAK1/2 degrader-1 inhibits the secretion of tumor necrosis factor- α (TNF- α) and interleukin-6 (IL-6). PROTAC JAK1/2 degrader-1 alleviates inflammatory responses and colon injury by inhibiting the JAK / STAT3 signaling pathway. PROTAC JAK1/2 degrader-1 can be used for the research of inflammatory bowel

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

disease [1]. (Pink: JAK1 and JAK2 ligand; Blue: Cereblon ligand; Black: linker).

In Vivo, PROTAC JAK1/2 degrader-1 (compound A8) (10-40 mg/kg; p.o.; daily; 7 days) alleviates DSS-induced colitis in C57BL/6 mice via downregulation of the JAK/STAT3 signaling pathway[1].

In Vitro, PROTAC JAK1/2 degrader-1 (compound A8) (3 μ M; 1 h followed by 6 h LPS stimulation) degrades JAK1 protein in LPS-stimulated Raw 264.7 cells[1]. PROTAC JAK1/2 degrader-1 (0.469-60 μ M; 24 h) shows no cytotoxicity in Raw 264.7 cells[1]. PROTAC JAK1/2 degrader-1 (0.47-60 μ M) induces dose-dependent degradation of JAK1 in LPS-stimulated Raw 264.7 cells with a DC₅₀ of 1.40 μ M[1]. PROTAC JAK1/2 degrader-1 (1.5 μ M; 3 μ M MG132) mediates JAK1 degradation in Raw 264.7 cells via a proteasome-dependent pathway, as degradation is inhibited by MG132, and the separate warhead and E3 ligase ligand components do not induce degradation[1]. PROTAC JAK1/2 degrader-1 (0.47-60 μ M) is a selective JAK1/2 degrader, dose-dependently degrading JAK2 with a DC₅₀ of 0.92 μ M while not affecting JAK3 or TYK2 levels at concentrations up to 60 μ M in Raw 264.7 cells[1]. PROTAC JAK1/2 degrader-1 (0.469-60 μ M; 24 h) suppresses NO production in LPS-stimulated Raw 264.7 cells in a dose-dependent manner, with significant inhibition starting at 0.469 μ M[1]. PROTAC JAK1/2 degrader-1 (0.05-60 μ M; 24 h) suppresses IL-6 and TNF- α secretion in LPS-stimulated Raw 264.7 cells with IC₅₀ values of 12.89 μ M and 17.17 μ M, respectively [1].

References:

[1]. Li G, et al. Development of potent JAK1/2 PROTAC degraders for the treatment of inflammatory bowel diseases. European journal of medicinal chemistry. 2026 Jan 15;302(Pt 3):118374.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA